论文部分内容阅读
膦乙酰-L-天冬氨酸酯(PALA)是一种能使尿核苷酸库耗竭的天冬氨酸氨甲酰转移酶抑制剂。在临床前模型中能选择性地增强5-氟尿嘧啶(5-FU)的抗癌活性。由于PALA与5-FU伍用治疗结肠癌的有效率达43％,所以作者将这一方案用于晚期胰腺癌的临床Ⅱ期试验。 41例未经细胞毒剂化疗的受试病人,男23例,女18例,中位年龄66岁(38～79岁)。治疗前后分别进行常规血象、血清生化指标测定和X-射线扫描等检查。治疗第1天用皮下iv插管和手提式输液泵快速输注
Phosphine acetyl-L-aspartate (PALA) is an aspartate transcarbamylase inhibitor that depletes the pool of uridine nucleotides. The anticancer activity of 5-fluorouracil (5-FU) can be selectively enhanced in preclinical models. Since the effective rate of PALA and 5-FU in the treatment of colon cancer is 43%, the authors will use this protocol for clinical phase II trials of advanced pancreatic cancer. Forty-one patients without chemotherapy with cytotoxic agents included 23 males and 18 females, with a median age of 66 years (38-79 years). Routine hemograms, serum biochemical indicators, and X-ray scans were performed before and after treatment. On the first day of treatment, rapid infusion with subcutaneous iv cannula and portable infusion pump